Business Wire·Sep 10, 2026, 9:11 PM ET

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

Yarrow Bioscience, Inc. priced an underwritten public offering of 5,769,231 shares of common stock at $26.00 per share.
The offering is expected to generate approximately $150 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.
The transaction is scheduled to close on September 14, 2026, subject to customary closing conditions.
Underwriters were granted a 30-day option to purchase up to an additional 865,384 shares at the public offering price less discounts.
Jefferies, TD Cowen, Guggenheim Securities, and LifeSci Capital are acting as joint book-running managers and lead managers for the offering.
Net proceeds will be used to fund research and development expenses for the company's pipeline and general corporate purposes.
A Form S-3 shelf registration statement was declared effective by the SEC on August 19, 2026.
The offering involves a potential merger with VYNE Therapeutics, Inc., with associated risks regarding future financial results and business relationships.
Yarrow is a clinical-stage biotechnology company developing YB-101, a first-in-class monoclonal antibody for autoimmune thyroid diseases.